January 19, 2021 5:35pm

Numbers based facts speak better then opinion as I see answers in numbers

Pre-open indication: 2 HITs and 3 MISS

Are we here to make money or see share pricing erode as earnings LPS (loss-per-share) season is about to begin? 

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting!

The Dow closed UP +115.26 points (+0.38); the S&P closed UP +30.86 points (+0.81%) while the Nasdaq closed UP +198.68 points (+1.53%)



Indexes edged higher on Tuesday after rebounding post a holiday and a rough week,

The S&P 500 lost 1.5% for its first weekly loss in three (3), while the Dow slid -0.9% and the Nasdaq dived -1.5, both posting their first negative week in five (5).


Sentiment and COVID-19 infections:

Janet Yellen, President-elect Biden’s designated nominee for Treasury Secretary and a former chair of the Federal Reserve, appeared before the Senate Finance Committee on Tuesday. “Neither the president-elect, nor I, propose this relief package without an appreciation for the country’s debt burden. <CNBC>

Infection cases <Million>: never to forget …

  • Tuesday 24.08 M cases,
  • Tuesday’s death rate totaled 399,111 <Johns Hopkins University>


This a.m.’s post, “expected rebound but, questionable indicators. A hope, a wing and a prayer for something to fulfill which expectation “… https://www.regmedinvestors.com/articles/11725


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Tuesday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 20/13 and 2 flats, closing positive at 18/14, 2 flats and 1 acquired;
  • Monday was holiday
  • Friday opened positive at 27/7 and 1 flat, flipped negative at the mid-day to 14/20 and 1 flat, closing negative at 10/24 and 1 acquired;


Pre-open indication:

  • 2 HITs <BUY: Fate Therapeutics (FATE +$0.72), SELL into strength: Global Blood Therapeutics (GBT +$0.93); 3 MISS < Maintaining SELL: Biostage (BSTG +$0.19 with 18,420 shares traded (a whole lot of “pumpin’ going-on), BUY: Mesoblast (MESO -$0.27); BUY:  Pluristem (PSTI -$0.17)>


Key metrics:

  • Sector volume was MODERATE with 5 of the 18-upside having higher than the 3-month average volume with the increased volume of 7 of 14-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 18-upside were +0.63% (FATE) to +15.57% (BSTG) while the 14-downside ranges from -0.07% (KDNY) to -6.64% (SLDB);


There are clear winners — and losers — heading into the first month of 2021.

52-week high:

  • Cellectis SA (CLLS) reached a 52-week high of $34.09

Jumping with share pricing momentum:

  • Cellectis SA (CLLS), Alnylam Pharmaceuticals (ALNY), Intellia therapeutics (NTLA), Global Blood Therapeutics (GBT), Ultragenyx (RARE) to name 5 of the 18 inclining of the 35 covered

Hammered in today’s market:

  • Editas Medicine (EDIT), Sage Therapeutics (SAGE), CRISPR Therapeutics (CRSP), bluebird bio (BLUE), Regenxbio (RGNX) to name 5 of the 14 declining of the 35 covered


Tuesday’s (10 of 18) incliners:

  • Cellectis SA (CLLS +$2.34);
  • Alnylam Pharmaceuticals (ALNY +$2.05 after Friday’s +$1.29);
  • Intellia Therapeutics (NTLA +$1.79 after Friday’s -$1.41);
  • Global Blood Therapeutics (GBT +$0.93 after Friday’s +$0.15);
  • Ultragenyx (RARE +$0.90 after Friday’s -$1.90);
  • Adverum Biotechnologies (ADVM +$0.80);
  • BioLife Solutions (BLFS +$0.79 after Friday’s -$1.60);
  • Fate Therapeutics (FATE +$0.72 after Friday’s -$3.81);
  • uniQure NV (QURE +$0.57);
  • Homology Medicine (FIXX +$0.29);

Tuesday’s (10 of 14) decliners:

  • Editas Medicine (EDIT -$4.03 after Friday’s +$0.22);
  • Sage Therapeutics (SAGE -$1.83 after Friday’s -$5.38);
  • CRISPR Therapeutics (CRSP -$1.59);
  • bluebird bio (BLUE -$1.02 after Friday’s -$1.32);
  • Regenxbio (RGNX -$0.49 after Friday’s -$1.61);
  • Solid Biosciences (SLDB -$0.43 after Friday’s +$0.02);
  • AxoGen (AXGN -$0.33 after Friday’s -$0.63);
  • Mesoblast (MESO -$0.27);
  • Ionis Pharmaceuticals (IONS -0.25);
  • Sangamo Therapeutics (SGMO -$0.25)

Closing flat 2 Verastem (VSTM), ReNeuron (RENE.L and 1 -Stemline Therapeutics (STML – acquired)



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +1.93% and XBI closed up +1.64%
  • Monday was holiday
  • Friday, the IBB closed down -0.16% and XBI closed down -1.11%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -1.10 points or -4.52% at 23.24
  • Monday was a holiday
  • Friday was up +1.09 points or +4.69% at 24.34

Upside volume:

  • Tuesday: 5 out of the 18-upside had higher than the 3-month average volume;
  • Monday was a holiday
  • Friday: 5 out of the 10-upside had higher than the 3-month average volume;

Downside volume:

  • Tuesday: 7 out of the 14-downside had higher than the 3-month average volume;
  • Monday was a holiday
  • Friday: 10 out of the 24-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Tuesday’s percentage (%) of the 18-upside were +0.63% (FATE) to +15.57% (BSTG) while the 14-downside ranges from -0.07% (KDNY) to -6.64% (SLDB);
  • Monday was a holiday
  • Friday’s percentage (%) of the 10-upside were +0.29% (EDIT) to +14.04% (RENE.L) while the 24-downside ranges from -0.10% (CLLS) to -6.97% (PGEN);


January, the 1st month of Q1 …

Tuesday closed positive with 18 advancers, 14 decliners, 2 flats and 1 acquired

Monday (1/18) was a holiday

Friday closed negative with 10 advancers, 24 decliners and 1 acquired

Thursday closed positive with 27 advancers, 7 decliners and 1 acquired

Wednesday closed positive with 10 advancers, 21 decliners and 4 flats

Tuesday closed positive with 21 advancers, 13 decliners and 1 flat

Monday (1/11) closed negative with 13 advancers, 20 decliners and 2 flats

Friday closed negative with 16 advancers, 18 decliners and 1 flat

Thursday closed positive with 31 advancers, 2 decliners and 2 flats

Wednesday closed positive with 22 advancers, 12 decliners and 1 flat

Tuesday closed positive with 19 advancers, 14 decliners and 2 flats

Monday (1/4) closed positive with 26 advancers, 7 decliners and 2 flats


The Bottom Line: Stocks rose Tuesday as traders returned from a long holiday weekend in the U.S. and eyed signs of mounting support for significant fiscal stimulus out of Washington.

There is STILL a short-term tone shift in the market.

The more important question is whether sector equities (not when) will rise and why they will appreciate?

I keep reiterating, “sector volatility remains fluid … as I had stated, “you should take some profits even if some money is left on the table – safety is cash in your pocket of portfolio!”

To make money in this sector, one has to know when to get out and which individual equity you should stay in!

Forewarned … Earnings LPS (los-per-share) season is coming quickly – my advice, trim and skim!!


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.